Tech Company Financing Transactions
Crossbow Therapeutics Funding Round
Crossbow Therapeutics, based in Cambridge, secured $77 million from Arkin Bio-Ventures, Taiho Ventures and BVF Partners.
Transaction Overview
Company Name
Announced On
3/19/2026
Transaction Type
Venture Equity
Amount
$77,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to expand operations and R&D efforts.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1030 Massachusetts Ave. 210
Cambridge, MA 02138
USA
Cambridge, MA 02138
USA
Phone
Website
Email Address
Overview
Crossbow Therapeutics, Inc., is a biotechnology company determined to improve the lives of people with cancer by unlocking the therapeutic potential of T-cell receptor (TCR)-mimetic antibodies. The company's T-Bolt� therapies are next-generation, easily assembled immunotherapies directed with high precision at previously unreachable cancer cell targets. Crossbow's efficient and selective approach is designed to target the entire universe of cancer proteins, dramatically expanding the potential of antibody therapy to address many types of cancer.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Briggs Morrison
Chief Scientific Officer
Dmitri Wiederschain
Co-Founder
Geraldine Paulus
Browse more venture capital transactions:
Prev: 3/19/2026: Deeptune venture capital transaction
Next: 3/19/2026: Edra venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on funding rounds that are announced publicly. VC investment data records reported here are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs